Biomotion Sciences (SLXN) Stock Forecast
SLXN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +3,168.0% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $0.15 – $36.40
SLXN analyst ratings
2 analystsNumber of analysts at each rating.
SLXN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SLXN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.91 | −$0.91 | −$0.91 | −$28.80 | +96.8% | 1 |
| Current fiscal year (2026) | −$4.84 | −$4.99 | −$4.70 | −$89.60 | +94.6% | 2 |
| Next fiscal year (2027) | −$2.02 | −$2.21 | −$1.84 | −$4.84 | +58.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SLXN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
SLXN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SLXN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$13.30 | −$13.30 | −$1.52 | −$1.52 | −$0.91 | −93.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$41.20 | −$5.31 | −$4.99 | −$4.99 | −$4.84 | −88.2% | 0 up · 0 down |
| Next fiscal year (2027) | −$28.65 | −$18.52 | −$18.61 | −$18.61 | −$2.02 | −92.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SLXN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SLXN beat in 2 of 6.
What analysts expect from SLXN
2 analysts cover Biomotion Sciences; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 3,168.0% above the latest close of $0.15. Analysts expect earnings of −$4.84 per share for 2026, +94.6% from a year earlier. For 2027 the average estimate is −$2.02 per share. Biomotion Sciences beat the EPS estimate in 2 of the last 6 quarters.
Related: SLXN income statement, SLXN key metrics, SLXN chart. See the SLXN stock overview for the latest quote and news.
SLXN forecast FAQ
What is Biomotion Sciences's price target?
The average analyst price target for Biomotion Sciences is $5.00, 3,168.0% above the latest close of $0.15.
Is Biomotion Sciences a buy, hold or sell?
Of 2 analysts covering Biomotion Sciences, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Biomotion Sciences's EPS forecast?
Analysts forecast −$4.84 per share for 2026 (range −$4.99 to −$4.70); for 2027 the estimate is −$2.02.
When does Biomotion Sciences report earnings?
Biomotion Sciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does Biomotion Sciences usually beat earnings estimates?
Biomotion Sciences reported EPS at or above the analyst estimate in 2 of the last 6 quarters.